We are placing our fair value estimate for Spectrum Brands SPC under review as we assess the firm's announcement Monday that third-quarter results will be below expectations. At this point, management's credibility is completely spent. This warning joins a long list of others the firm has issued ...
We think Emmis faces several headwinds that will limit its long-term growth.
Somaxon has bet everything on Silenor for insomnia.
Plus, a new Vanguard fund, changes at Fidelity, and more.